Proteonomix Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial with UMK-121 in Patients with End-Stage Liver Disease

<0> Demonstrates Proteonomix’s ability to advance research into clinical trial </0>

Proteonomix Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial with UMK-121 in Patients with End-Stage Liver Disease

Proteonomix, Inc.Michael Cohen, CEO973-544-6116orLHAJody [email protected]_IR_PR

(OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121. The Proteonomix-sponsored trial will evaluate UMK-121 in patients with end-stage liver disease (ESLD).

“Permission by the FDA marks an important milestone in our plans to initiate a Company-sponsored clinical trial with UMK-121, following years of research and investment to advance development of this drug candidate,” said Proteonomix Chief Technology Officer Steven Byle. “We hope and anticipate that this trial will demonstrate the potential of UMK-121 to mobilize stem cells in order to improve liver function in patients with ESLD. We consider ourselves fortunate to be involved with a development-stage therapy that could improve the life expectancy for this class of terminally ill patients awaiting liver transplants.”

Proteonomix CEO Michael Cohen added, “This is a significant step for our Company as this is the first FDA IND to be held by Proteonomix and demonstrates the ability of the Company to move basic research projects into clinical trials.”

UMK-121 is a patent-pending combination of two FDA-approved drugs designed to mobilize mesenchymal stem cells from the bone marrow to the peripheral circulation. The combination drug is designed to reduce inflammation and increase angiogenesis to restore liver function. UMK-121 was developed by Proteonomix Chief Scientific Officer Ian McNiece and President and CEO Michael Cohen, and subsequently licensed to Proteonomix through its wholly owned subsidiary Thor Biopharma, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and plans to file an IND application for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at and .

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.